Targeting NF-κB: A Promising Molecular Therapy in Inflammatory Arthritis

REFERENCES

• Firestein G. S. Evolving concepts of rheumatoid arthritis. Nature 200; 423: 356–361
   Google Scholar
• Pelletier J. P., Martel-Pelletier J., Abramson S. Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237–1247
   PubMed Web of Science ®Google Scholar
• Firestein G. S., Manning A. M. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999; 42: 609–621
   PubMed Web of Science ®Google Scholar
• Li Q., Verma I. M. NF-κ B regulation in the immune system. Nat Rev Immunol 2002; 2: 725–734
   PubMed Web of Science ®Google Scholar
• Silverman N., Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev 2001; 15: 2321–2342
   PubMed Web of Science ®Google Scholar
• Ghosh S., Karin M. Missing pieces in the NF-κ B puzzle. Cell 2002; 109: S81–S96
   PubMed Web of Science ®Google Scholar
• Bouwmeester T., Bauch A. H Ruffner, P.O Angrand et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004; 6: 97–105
   PubMed Web of Science ®Google Scholar
• Hayden M. S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344–362
   PubMed Web of Science ®Google Scholar
• Udalova I. A., Mott R., Field D., Kwiatkowski D. Quantitative prediction of NF-κ B DNA–protein interactions. Proc Natl Acad Sci USA 2002; 99: 8167–8172
   PubMed Web of Science ®Google Scholar
• Dejardin E., et al. The lymphotoxin–β receptor induces different patterns of gene expression via two NF-κ B pathways. Immunity 2002; 17: 525–535
   PubMed Web of Science ®Google Scholar
• Yamamoto Y., Gaynor R. B. IκB kinases: key regulators of the NF-κ B pathway. Trends Biochem Sci 2004; 29: 72–79
   PubMed Web of Science ®Google Scholar
• Yamaoka S., et al. Complementation cloning of NEMO, a component of the IKK complex essential for NF-κ B activation. Cell 1998; 93: 1231–1240
   PubMed Web of Science ®Google Scholar
• Häcker H., Karin M. Regulation and function of IKK and IKK–related kinases. Sci STKE 2006; 357: re13
   Google Scholar
• Yamamoto Y., Verma U. N., Prajapati S., Kwak Y. T., Gaynor R. B. Histone H3 phosphorylation by IKK–alpha is critical for cytokine–induced gene expression. Nature 2003; 423: 655–659
   PubMed Web of Science ®Google Scholar
• Anest J. L., Hanson P. C., Cogswell K. A., Steinbrecher Strahl B. D., Baldwin A. S. A nucleosomal function for IkappaB kinase–alpha in NF–kappaB–dependent gene expression. Nature 2003; 423: 659–663
   PubMed Web of Science ®Google Scholar
• Dejardin E. The alternative NF–kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 2006; 72: 1161–1179
   PubMed Web of Science ®Google Scholar
• Roman-Blas J. A., Jimenez S. A. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2006; 14: 839–848
   PubMed Web of Science ®Google Scholar
• Uwe S. Anti–inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol 2008; 75: 1567–1579
   PubMed Web of Science ®Google Scholar
• Groesdonk H. V., Schlottmann S., Richter F., Georgieff M., Senftleben U. Escherichia coli prevents phagocytosis–induced death of macrophages via classical NF–kappaB signaling, a link to T–cell activation. Infect Immun 2006; 74: 5989–6000
   Google Scholar
• Hayden M. S., West A. P., Ghosh S. NF-kappaB and the immune response. Oncogene 2006; 25: 6758–6780
   PubMed Web of Science ®Google Scholar
• Zanetti M., Castiglioni P., Schoenberger S., Gerloni M. The role of relB in regulating the adaptive immune response. Ann N Y Acad Sci 2003; 987: 249–257
   Google Scholar
• Theilgaard-Mönch K., Jacobsen L. C., Borup R., Rasmussen T., Bjerregaard M. D., Nielsen F. C., Cowland J. B., Borregaard N. The transcriptional program of terminal granulocytic differentiation. Blood 2005; 105: 1785–1796
   Google Scholar
• McDonald P. P., Bald A., Cassatella M. A. Activation of the NF–kappaB pathway by inflammatory stimuli in human neutrophils. Blood 1997; 89: 3421–3433
   PubMed Web of Science ®Google Scholar
• Horwitz B. H., Zelazowski P., Shen Y., Wolcott K. M., Scott M. L., Baltimore D., Snapper C. M. The p65 subunit of NF–kappa B is redundant with p50 during B cell proliferative responses, and is required for germline CH transcription and class switching to IgG3. J Immunol 1999; 162: 1941–1946
   Google Scholar
• Weih F., Caamaño J. Regulation of secondary lymphoid organ development by the nuclear factor–kappaB signal transduction pathway. Immunol Rev 2003; 195: 91–105
   PubMed Web of Science ®Google Scholar
• Ware C. F. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005; 23: 787–819
   PubMed Web of Science ®Google Scholar
• Handel M. L., McMorrow L. B., Gravallese E. M. Nuclear factor-kappaB n rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995; 38: 1762–1770
   PubMed Web of Science ®Google Scholar
• Benito M. J., Murphy E., Murphy E. P., van den Berg W. B., FitzGerald O., Bresnihan B. Increased synovial tissue NF–kappa B1 expression at sites adjacent to the cartilage–pannus junction in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1781–1787
   PubMedGoogle Scholar
• Aupperle K., Bennett B., Han Z., Boyle D., Manning A., Firestein G. NF-kappaB regulation by IkappaB kinase–2 in rheumatoid artritis synoviocytes. J Immunol 2001; 166: 2705–2711
   PubMed Web of Science ®Google Scholar
• Han Z., Boyle D. L., Manning A. M., Firestein G. S. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen–induced arthritis. Autoimmunity 1998; 28: 197–208
   PubMed Web of Science ®Google Scholar
• Eguchi J., Koshino T., Takagi T., Hayashi T., Saito T. NF-kappa B I-kappa B overexpression in articular chondrocytes with progression of type II collagen–induced arthritis in DBA/1 mouse knees. Clin Exp Rheumatol 2002; 20: 647–652
   Google Scholar
• Tsao P. W., Suzuki T., Totsuka R., Murata T., Takagi T., Ohmachi Y., Fujimura H., Takata I. The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Clin Immunol Immunopathol 1997; 83: 173–178
   PubMedGoogle Scholar
• Tak P. P., Gerlag D. M., Aupperle K. R., van de Geest D. A., Overbeek M., Bennett B. L., Boyle D. L., Manning A. M., Firestein G. S. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001; 47: 1897–1907
   Google Scholar
• Theoleyre S., Wittrant Y., Tat S. K., Fortun Y., Redini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004; 15: 457–475
   PubMed Web of Science ®Google Scholar
• Dougall W. C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., Daro E., Smith J., Tometsko M. E., Maliszewski C. R., Armstrong A., Shen V., Bain S., Cosman D., Anderson D., Morrissey P. J., Peschon J. J., Schuh J. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13: 2412–2424
   PubMed Web of Science ®Google Scholar
• Kong Y. Y., Yoshida H., Sarosi I., Tan H. L., Timms E., Capparelli C., Morony S., Oliveira-dos-Santos A. J., Van G., Itie A., Khoo W., Wakeham A., Dunstan C. R., Lacey D. L., Mak T. W., Boyle W. J., Penninger J. M. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph–node organogenesis. Nature 1999; 397: 315–323
   PubMed Web of Science ®Google Scholar
• Iotsova V., Caamaño J., Loy J., Yang Y., Lewin A., Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3: 1285–1289
   PubMed Web of Science ®Google Scholar
• Ruocco M. G., Karin M. Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy. Adv Exp Med Biol 2007; 602: 125–134
   Google Scholar
• Aya K., Alhawagri M., Hagen-Stapleton A., Kitaura H., Kanagawa O., Novack D. V. NF–[kappa) B–inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005; 115: 1848–1854
   PubMed Web of Science ®Google Scholar
• Vaira S., Johnson T., Hirbe A. C., Alhawagri M., Anwisye I., Sammut B., O'Neal J., Zou W., Weilbaecher K. N., Faccio R., Novack D. V. RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA 2008; 105: 3897–3902
   Google Scholar
• Sioud M., Mellbye O., Førre O. Analysis of the NF–kappa B p65 subunit, Fas antigen, Fas ligand and Bcl-2-related proteins in the synovium of RA and polyarticular JRA. Clin Exp Rheumatol 1998; 16: 125–134
   PubMed Web of Science ®Google Scholar
• Varsani H., Patel A., van Kooyk Y., Woo P., Wedderburn L. R. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF–kappaB [RANK). Rheumatology 2003; 42: 583–590
   PubMed Web of Science ®Google Scholar
• Collantes E., Valle Blázquez M., Mazorra V., Macho A., Aranda E., Muñoz E. Nuclear factor–kappa B activity in T cells from patients with rheumatic diseases: a preliminary report. Ann Rheum Dis 1998; 57: 738–741
   PubMedGoogle Scholar
• Eggert M., Seeck U., Semmler M., Maass U., Dietmann S., Schulz M., Dotzlaw H., Neeck G. An evaluation of anti-TNF-alpha-therapy in patients with ankylosing spondylitis: imbalanced activation of NF kappa B subunits in lymphocytes and modulation of serum cortisol concentration. Rheumatol Int 2007; 27: 841–846
   PubMed Web of Science ®Google Scholar
• Danning C. L., Illei G. G., Hitchon C., Greer M. R., Boumpas D. T., McInnes I. B. Macrophage–derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43: 1244–1256
   PubMed Web of Science ®Google Scholar
• Lories R. J., Derese I., Luyten F. P., de Vlam K. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008; 26: 96–102
   PubMed Web of Science ®Google Scholar
• Liu R., O'Connell M., Johnson K., Pritzker K., Mackman N., Terkeltaub R. Extracellular signal–regulated kinase 1/extracellular signal–regulated kinase 2 mitogen–activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin–8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000; 43: 1145–1155
   PubMedGoogle Scholar
• Jaramillo M., Godbout M., Naccache P. H., Olivier M. Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals. J Biol Chem 2004; 279: 52797–52805
   Google Scholar
• Jaramillo M., Naccache P. H., Olivier M. Monosodium urate crystals synergize with IFN–gamma to generate macrophage nitric oxide: involvement of extracellular signal–regulated kinase 1/2 and NF–kappa B. J Immunol 2004; 172: 5734–5742
   PubMed Web of Science ®Google Scholar
• McCarthy G. M., Augustine J. A., Baldwin A. S., Christopherson P. A., Cheung H. S., Westfall P. R., Scheinman R. I. Molecular mechanism of basic calcium phosphate crystal–induced activation of human fibroblasts. Role of nuclear factor kappab, activator protein 1, and protein kinase c. J Biol Chem 1998; 273: 35161–35169
   PubMed Web of Science ®Google Scholar
• Gjertsson I., Hultgren O. H., Collins L. V., Pettersson S., Tarkowski A. Impact of transcription factors AP-1 and NF-kappaB on the outcome of experimental Staphylococcus aureus arthritis and sepsis. Microbes Infect 2001; 3: 527–534
   Google Scholar
• Yip K. H., Zheng M. H., Feng H. T., Steer J. H., Joyce D. A., Xu J. Sesquiterpene lactone parthenolide blocks lipopolysaccharide–induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 2004; 19: 1905–1916
   PubMed Web of Science ®Google Scholar
• Wong H. K., Kammer G. M., Dennis G., Tsokos G. C. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65–RelA protein expression. J Immunol 1999; 163: 1682–168
   PubMed Web of Science ®Google Scholar
• Herndon T. M., Juang Y. T., Solomou E. E., Rothwell S. W., Gourley M. F., Tsokos G. C. Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin–2 promoter activity. Clin Immunol 2002; 103: 145–153
   PubMedGoogle Scholar
• Burgos P., Metz C., Bull P., Pincheira R., Massardo L., Errázuriz C., Bono R., Jacobelli S., González A. Increased expression of c-rel, from the NF–kappaB/Rel family, in T cells from patients with systemic lupus erythematosus. J Rheumatol 2000; 27: 116–127
   PubMedGoogle Scholar
• Enzler T., Bonizzi G., Silverman G. J., Otero D. C., Widhopf G. F., Anzelon-Mills A., Rickert R. C., Karin M. Alternative and classical NF–kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus–like disease. Immunity 2006; 25: 403–415
   PubMed Web of Science ®Google Scholar
• Choi J. Y., Gao W., Odegard J., Shiah H. S., Kashgarian M., McNiff J. M., Baker D. C., Cheng Y. C., Craft J. Abrogation of skin disease in LUPUS–prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis Rheum 2006; 54: 3277–3283
   Google Scholar
• Roman-Blas J. A., Stokes D. G., Jimenez S. A. Modulation of TGF–beta signaling by proinflammatory cytokines in articular chondrocytes. Osteoarthritis Cartilage 2007; 15: 1367–1377
   PubMed Web of Science ®Google Scholar
• Seguin C. A., Bernier S. M. TNFalpha suppresses link protein and type II collagen expression in chondrocytes: role of MEK1/2 and NF–kappaB signaling pathways. J Cell Physiol 2003; 197: 356–369
   PubMed Web of Science ®Google Scholar
• Liacini A., Sylvester J., Li W. Q., Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 [AP-1) and nuclear factor kappa B [NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 2002; 21: 251–262
   PubMed Web of Science ®Google Scholar
• Liacini A., Sylvester J., Li W. Q., Huang W., Dehnade F., Ahmad M., Zafarullah M. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 2003; 288: 208–217
   PubMed Web of Science ®Google Scholar
• Pulai J. I., Chen H., Im H. J., Kumar S., Hanning C., Hegde P. S., Loeser R. F. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 2005; 174: 5781–5788
   PubMed Web of Science ®Google Scholar
• Forsyth C. B., Cole A., Murphy G., Bienias J. L., Im H. J., Loeser R. F., Jr. Increased matrix metalloproteinase–13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A Biol Sci Med Sci 2005; 60: 1118–1124
   PubMed Web of Science ®Google Scholar
• Martin G., Andriamanalijaona R., Grassel S., Dreier R., Mathy-Hartert M., Bogdanowicz P., Boumediene K., Henrotin Y., Bruckner P., Pujol J. P. Effect of hypoxia and reoxygenation on gene expression and response to interleukin–1 in cultured articular chondrocytes. Arthritis Rheum 2004; 50: 3549–3560
   PubMedGoogle Scholar
• Agarwal S., Deschner J., Long P., Verma A., Hofman C., Evans C. H., Piesco N. Role of NF–kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 2004; 50: 3541–3548
   PubMed Web of Science ®Google Scholar
• Dossumbekova A., Anghelina M., Madhavan S., He L., Quan N., Knobloch T., Agarwal S. Biomechanical signals inhibit IKK activity to attenuate NF–kappaB transcription activity in inflamed chondrocytes. Arthritis Rheum 2007; 56: 3284–3296
   PubMed Web of Science ®Google Scholar
• Kuhn K., Hashimoto S., Lotz M. IL–1 beta protects human chondrocytes from CD95–induced apoptosis. J Immunol 2000; 164: 2233–2239
   Google Scholar
• Kim S. J., Hwang S. G., Shin D. Y., Kang S. S., Chun J. S. p38 kinase regulates nitric oxide–induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B–dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem 2002; 277: 33501–33508
   PubMed Web of Science ®Google Scholar
• Kim S. J., Chun J. S. Protein kinase C alpha and zeta regulate nitric oxide–induced NF–kappa B activation that mediates cyclooxygenase–2 expression and apoptosis but not dedifferentiation in articular chondrocytes. Biochem Biophys Res Commun 2003; 303: 206–211
   PubMed Web of Science ®Google Scholar
• Yamamoto Y., Gaynor R. Therapeutic potential of inhibition of the NF-κ B pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135–142
   PubMed Web of Science ®Google Scholar
• De Bosscher K., Vanden Berghe W., Haegeman G. Mechanisms of anti–inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109: 16–22
   PubMed Web of Science ®Google Scholar
• Auphan N., DiDonato J. A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF–kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286–290
   PubMed Web of Science ®Google Scholar
• Scheinman R. I., Cogswell P. C., Lofquist A. K., Baldwin A. S., Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283–286
   PubMed Web of Science ®Google Scholar
• De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000; 97: 3919–3924
   PubMed Web of Science ®Google Scholar
• De Bosscher K., Schmitz M. L., Vanden Berghe W., Plaisance S., Fiers W., Haegeman G. Glucocorticoid–mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 1997; 94: 13504–13509
   PubMed Web of Science ®Google Scholar
• Sheppard K. A., Rose D. W., Haque Z. K., Kurokawa R., McInerney E., Westin S., Thanos D., Rosenfeld M. G., Glass C. K., Collins T. Transcriptional activation by NF–kappaB requires multiple coactivators. Mol Cell Biol 1999; 19: 6367–6378
   PubMed Web of Science ®Google Scholar
• Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase–independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057–2072
   PubMed Web of Science ®Google Scholar
• Takada Y., Bhardwaj A., Potdar P., Aggarwal B. B. Nonsteroidal anti–inflammatory agents differ in their ability to suppress NF–kappaB activation, inhibition of expression of cyclooxygenase–2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247–9258
   PubMed Web of Science ®Google Scholar
• Wahl C., Liptay S., Adler G., Schmid R. M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163–1174
   PubMed Web of Science ®Google Scholar
• Meyer Z., Kohler N. G., Joly A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett 1997; 413: 354–358
   PubMed Web of Science ®Google Scholar
• Venkataraman L., Burakoff S. J., Sen R. FK506 inhibits antigen receptor–mediated induction of c-rel in B and T lymphoid cells. J Exp Med 1995; 181: 1091–1099
   PubMedGoogle Scholar
• Chadwick C. C., Chippari S., Matelan E., Borges-Marcucci L., Eckert A. M., Keith J. C., Jr., Albert L. M., Leathurby Y., Harris H. A., Bhat R. A., Ashwell M., Trybulski E., Winneker R. C., Adelman S. J., Steffan R. J., Harnish D. C. Identification of pathway–selective estrogen receptor ligands that inhibit NF–kappaB transcriptional activity. Proc Natl Acad Sci USA 2005; 102: 2543–2548
   PubMed Web of Science ®Google Scholar
• Keith J. C., Jr., Albert L. M., Leathurby Y., Follettie M., Wang L., Borges-Marcucci L., Chadwick C. C., Steffan R. J., Harnish D. C. The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor–kappa B transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R427–438
   PubMed Web of Science ®Google Scholar
• Firestein G. S. NF-κ B: Holy Grail for rheumatoid arthritis?. rthritis Rheum 2004; 50: 2381–2386
   PubMed Web of Science ®Google Scholar
• Bacher S., Schmitz M. L. The NF–kappaB pathway as a potential target for autoimmune disease therapy. Curr Pharm Des 2004; 10: 2827–2837
   PubMedGoogle Scholar
• Feldmann M., Andreakos E., Smith C., Bondeson J., Yoshimura S., Kiriakidis S., Monaco C., Gasparini C., Sacre S., Lundberg A., Paleolog E., Horwood N. J., Brennan F. M., Foxwell B. M. Is NF–kappaB a useful therapeutic target in rheumatoid arthritis?. Ann Rheum Dis 2002; 61(Suppl 2)ii13–18
   PubMedGoogle Scholar
• Smolen J. S., Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Rev Drug Dis 2003; 2: 473–488
   PubMed Web of Science ®Google Scholar
• Epinat J. C., Gilmore T. D. Diverse agents act at multiple levels to inhibit the Rel/NF–kappaB signal transduction pathway. Oncogene 1999; 18: 6896–6909
   PubMed Web of Science ®Google Scholar
• Elliott P. J., Zollner T. M., Boehncke W. H. Proteasome inhibition: a new anti–inflammatory strategy. J Mol Med 2003; 81: 235–245
   PubMed Web of Science ®Google Scholar
• Kawakami A., Nakashima T., Sakai H., Hida A., Urayama S., Yamasaki S., Nakamura H., Ida H., Ichinose Y., Aoyagi T., Furuichi I., Nakashima M., Migita K., Kawabe Y., Eguchi K. Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum 1999; 42: 2440–2448
   PubMed Web of Science ®Google Scholar
• Tomita T., Takeuchi E., Tomita N., Morishita R., Kaneko M., Yamamoto K., Nakase T., Seki H., Kato K., Kaneda Y., Ochi T. Suppressed severity of collagen–induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532–2542
   PubMed Web of Science ®Google Scholar
• Hashimoto H., Tomita T., Kunugiza Y., Nampei A., Morishita R., Kaneda Y., Yoshikawa H. NF-κ B Decoy oligodeoxynucleotides suppressed the progression of osteoarthritis in rat arthritis. Arthritis Rheum 2003; 48: S630
   Google Scholar
• Tilstra J., Rehman K. K., Hennon T., Plevy S. E., Clemens P., Robbins P. D. Protein transduction: identification, characterization and optimization. Biochem Soc Trans 2007; 35: 811–815
   PubMedGoogle Scholar
• Fujihara S. M., Cleaveland J. S., Grosmaire L. S., Berry K. K., Kennedy K. A., Blake J. J., Loy J., Rankin B. M., Ledbetter J. A., Nadler S. G. A D–amino acid peptide inhibitor of NF–kappa B nuclear localization is efficacious in models of inflammatory disease. J Immunol 2000; 165: 1004–1012
   PubMed Web of Science ®Google Scholar
• Tas S. W., Adriaansen J., Hajji N., Bakker A. C., Firestein G. S., Vervoordeldonk M. J., Tak P. P. Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno–associated virus type 5. Hum Gene Ther 2006; 17: 821–832
   PubMedGoogle Scholar
• Blackwell N. M., Sembi P., Newson J. S., Lawrence T., Gilroy D. W., Kabouridis P. S. Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane–permeable IkappaBalpha repressor. Arthritis Rheum 2004; 50: 2675–2684
   PubMed Web of Science ®Google Scholar
• Tas S. W., Vervoordeldonk M. J., Hajji N., May M. J., Ghosh S., Tak P. P. Local treatment with the selective IkappaB kinase beta inhibitor NEMO–binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 2006; 8: R86
   PubMed Web of Science ®Google Scholar
• Amos N., Lauder S., Evans A., Feldmann M., Bondeson J. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology 2006; 45: 1201–1209
   PubMed Web of Science ®Google Scholar
• Bondeson J., Lauder S., Wainwright S., Amos N., Evans A., Hughes C., Feldmann M., Caterson B. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor–kappaB–dependent. J Rheumatol 2007; 34: 523–533
   PubMed Web of Science ®Google Scholar
• Kishore N. A., Sommers C., Mathialagan S., et al. A selective IKK–2 inhibitor blocks NF–kappa B–dependent gene expression in interleukin–1 beta–stimulated synovial fibroblasts. J Biol Chem 2003; 278: 32861–32871
   PubMed Web of Science ®Google Scholar
• Podolin P. L., Callahan J. F., Bolognese B. J., Li Y. H., Carlson K., Davis T. G., Mellor G. W., Evans C., Roshak A. K. Attenuation of murine collagen–induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 [2-[[aminocarbonyl)amino]-5-[4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen–induced T cell Proliferation. J Pharmacol Exp Ther 2005; 312: 373–381
   PubMed Web of Science ®Google Scholar
• McIntyre K. W., Shuster D. J., Gillooly K. M., Dambach D. M., Pattoli M. A., Lu P, et al. A highly selective inhibitor of I kappa B kinase, BMS–345541, blocks both joint inflammation and destruction in collagen–induced arthritis in mice. Arthritis Rheum 2003; 48: 2652–2659
   PubMed Web of Science ®Google Scholar
• Schopf L., Savinainen A., Anderson K., Kujawa J., DuPont M., Silva M., Siebert E., Chandra S., Morgan J., Gangurde P., Wen D., Lane J., Xu Y, Hepperle M., Harriman G., Ocain T., Jaffee B. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum 2006; 54: 3163–3173
   PubMed Web of Science ®Google Scholar
• Izmailova E. S., Paz N., Alencar H., Chun M., Schopf L., Hepperle M., Lane J. H., Harriman G., Xu Y., Ocain T., Weissleder R., Mahmood U., Healy A. M., Jaffee B. Use of molecular imaging to quantify response to IKK–2 inhibitor treatment in murine arthritis. Arthritis Rheum 2007; 56: 117–128
   PubMed Web of Science ®Google Scholar
• Wakamatsu K., Nanki T., Miyasaka N., Umezawa K., Kubota T. Effect of a small molecule inhibitor of nuclear factor–kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005; 7: R1348–1359
   PubMed Web of Science ®Google Scholar
• Kubota T., Hoshino M., Aoki K., Ohya K., Komano Y., Nanki T., Miyasaka N., Umezawa K. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony–stimulating factor. Arthritis Res Ther 2007; 9: R97
   Web of Science ®Google Scholar
• Martin E., Capini C., Duggan E., Lutzky V. P., Stumbles P., Pettit A. R., O'Sullivan B., Thomas R. Antigen–specific suppression of established arthritis in mice by dendritic cells deficient in NF–kappaB. Arthritis Rheum 2007; 56: 2255–2266
   PubMedGoogle Scholar
• Millenium. Available at: http://investor.millenium.com/phoenix.zhtml?c=80159&p=irol–newsmediaArticle&ID=900341&highlight=. Press release August 30, 2006
   Google Scholar
• VGX Pharmaceutical. Available at: http://www.vgxp.com/PR011408.html. Press release January 14, 2008
   Google Scholar
• Jepsen J. S., Wengel J. LNA–antisense rivals siRNA for gene silencing. Curr Opin Drug Discov Devel 2004; 2: 188–194
   Google Scholar
• Heasman J. Morpholino oligos: making sense of antisense?. Dev Biol 2002; 243: 209–214
   PubMed Web of Science ®Google Scholar
• McManus M. T., Sharp P. A. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737–747
   PubMed Web of Science ®Google Scholar
• Huppi K., Martin S. E., Caplen N. J. Defining and assaying RNAi in mammalian cells. Molecular Cell 2005; 17: 1–10
   PubMed Web of Science ®Google Scholar
• Lianxu C., Hongti J., Changlong Y. NF–kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes. Osteoarthritis Cartilage 2006; 14: 367–376
   PubMed Web of Science ®Google Scholar
• Chen L. X., Lin L., Wang H. J., Wei X. L., Fu X., Zhang J. Y., Yu C. L. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector–mediated NF–kappaBp65–specific siRNA. Osteoarthritis Cartilage 2008; 16: 174–84
   PubMed Web of Science ®Google Scholar